Synthetic lethal interaction with BCL-XL blockade deepens response to cetuximab in patient-derived models of metastatic colorectal cancer.

Simonetta Maria Leto Martina Ferri Francesco Sassi Eugenia R Zanella Francesca Cottino Valentina Vurchio Irene Catalano Alessandro Ferrero Caterina C Zingaretti Caterina Marchio Elena Grassi Livio Trusolino Andrea Bertotti

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In mCRC tumors that respond to cetuximab, antibody treatment confers a synthetic-lethal dependency on BCL-XL. Targeting this dependency unleashes apoptosis and increases the depth of response to cetuximab.

Keyphrases

metastatic colorectal cancer
oxidative stress
endoplasmic reticulum stress
cell death
optical coherence tomography
cell cycle arrest
radiation therapy
drug delivery
signaling pathway